PositiveID’s FireflyDX Prototype Detects Flu Types; Chief Science Officer Explains Why Accurate Flu Detection at Point of Care Enables Smart Treatment Decisions in Interview with SmallCapVoice.com

AUSTIN, Texas, Jan. 31, 2018 -- SmallCapVoice.com, Inc. today announced it conducted a new audio interview with PositiveID Corporation (“PositiveID” or the “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, regarding the Company’s successful detection of the influenza virus on its FireflyDX real-time polymerase chain reaction (PCR) breadboard prototype system (“prototype system”). The interview can be heard at https://smallcapvoice.com/blog/1-30-18-smallcapvoice-interview-with-positiveid-corporation-psid.

In the interview, Dr. Kimothy Smith, Chief Science Officer of PositiveID and its ExcitePCR Corporation subsidiary, announced the Company’s successful detection of the influenza virus on its FireflyDX prototype system and its publication of a white paper.  Smith described the limitations of current rapid influenza detection tests, and discussed how FireflyDX could enable correct diagnosis at the point of care for smart treatment decisions.  PositiveID and ExcitePCR are developing FireflyDX, in both portable and handheld forms, to enable fast, accurate diagnosis at the point of care or point of need (POC/PON).

The FireflyDX family of products, currently under development, is designed to provide accurate, rapid pathogen detection using real-time PCR in less than 30 minutes, with minimally trained personnel and at a lower cost than existing systems. Current solutions for accurately identifying potential pathogens and bio-threats, especially at the POC/PON, can sometimes take as long as several hours to several days to provide results, dramatically delaying what is often life-saving treatment. Five different flu virus assays (Type A; Type B; H3N3; H7N1; and, H5N1) were tested on the FireflyDX prototype system in the lab. 

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.

About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

On August 24, 2017, PositiveID Corporation and its wholly-owned subsidiary PositiveID Diagnostics, Inc.  (collectively, the “Seller”), entered into an Asset Purchase Agreement (“APA”) with ExcitePCR Corporation. Pursuant to the APA, at closing, the Seller will sell and deliver to ExcitePCR all assets used in connection with the operation of the FireflyDX technology. For more information on the APA, please read PositiveID’s Form 8-K filed on August 28, 2017, which can be found here.

Statements about PositiveID's future expectations, including the likelihood that FireflyDX could enable correct diagnosis at the point of care for smart treatment decisions; the likelihood that PositiveID and ExcitePCR are developing FireflyDX, in both portable and handheld forms, to enable fast, accurate diagnosis at the POC/PON; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to complete the development, testing and commercialization of the FireflyDX-Portable and FireflyDX-Handheld; the Company’s ability to target the professional healthcare market; the Company’s ability to raise capital; the Company’s and ExcitePCR’s ability to close the APA; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on November 13, 2017, August 14, 2017, and May 15, 2017, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:
PositiveID Corporation
Allison Tomek
(561) 805-8044
[email protected]

Stuart Smith
SmallCapVoice.com
512-267-2430